Cassel | UlrichAMNOG-Check 2017

What do astronomical prices, mixed prices and the AMNOG paradox mean? Is the financing of statutory health insurance in Germany (GKV) at risk? Is there still the potential to save money? What is value-based pricing? What consequences has the ruling by the Higher Social Court of Berlin-Brandenburg regarding the lawfulness of mixed prices had? Are there already supply gaps for innovative drugs?

AMNOG-Check 2017 provides profound answers to these questions. After six years of AMNOG legislation, this study puts the new regulations to the test. It analyses early benefit assessment and price negotiations empirically up to the end of 2016.

Its authors, Dieter Cassel und Volker Ulrich, are proven experts in this field, having published numerous research articles and expert reports.